Article Details

FDA Approves Palbociclib for Male Patients With HR+/HER2- Breast Cancer

Retrieved on: 2019-04-04 02:42:49

Tags for this article:

Click the tags to see associated articles and topics

FDA Approves Palbociclib for Male Patients With HR+/HER2- Breast Cancer. View article details on HISWAI:

Excerpt

<div>The electronic health records and postmarketing reports that the approval is based on is sourced from the IQVIA Insurance database, <b>Flatiron Health</b> ...</div>

Article found on:

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up